Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management
Journal
Journal of Opioid Management
Journal Volume
15
Journal Issue
2
Date Issued
2019-01-01
Author(s)
O'Brien, Tony
Ahn, Jin Seok
Chye, Richard
Le, Brian
Lu, Henry
Olarte, Gabriel
Palladini, Mariana
Salti, Amar
Yaakup, Hayati
Buemio, Kristal Cielo
Colin, Consuelo Gutierrez
Hadjiat, Yacine
Abstract
© 2019 Journal of Opioid Management, All Rights Reserved. Transdermal buprenorphine (TDB) has demonstrated effectiveness in treating a range of chronic pain conditions, including cancer pain, nociceptive pain, and neuropathic pain and has a favorable safety profile. Worldwide, clinical experience of its use is relatively limited. There is considerable misunderstanding about the pharmacology, mechanism of action, and safety of buprenorphine. There is also limited guidance on the appropriate use of TDB for chronic pain management. This article presents an overview of TDB and also provides practical recommendations for its use as part of a multifaceted strategy in chronic cancer and non-cancer pain.
Subjects
Cancer pain | Chronic pain management | Neuropathic pain | Non-cancer pain | Practical guide | Transdermal buprenorphine
Cancer pain; Chronic pain management; Neuropathic pain; Non-cancer pain; Practical guide; Transdermal buprenorphine
SDGs
Other Subjects
buprenorphine; buprenorphine; narcotic analgesic agent; analgesia; Article; breakthrough pain; cancer pain; chronic pain; constipation; drug dose titration; drug efficacy; drug safety; drug tolerability; drug withdrawal; human; kidney failure; maintenance therapy; nausea; patient education; practice guideline; QTc interval; respiration depression; skin manifestation; vomiting; analgesia; chronic pain; complication; neoplasm; pain measurement; transdermal patch; Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Neoplasms; Pain Management; Pain Measurement; Transdermal Patch
Type
journal article